Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $6.00 | Buy | Rodman & Renshaw |
8/28/2023 | $28.00 → $5.00 | Overweight → Neutral | JP Morgan |
12/27/2022 | $19.00 | Buy | Chardan Capital Markets |
10/31/2022 | $15.00 | Buy | Guggenheim |
10/10/2022 | $28.00 | Buy | Canaccord Genuity |
5/23/2022 | $27.00 | Buy | H.C. Wainwright |
5/12/2022 | Mkt Perform | William Blair | |
11/19/2021 | $33.00 → $32.00 | Outperform | SVB Leerink |
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
144 - Century Therapeutics, Inc. (0001850119) (Subject)
144 - Century Therapeutics, Inc. (0001850119) (Subject)
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows: Abstract Number: 1380Title: C
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripoten
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows: